Director George J. Morrow of Neurocrine Biosciences Inc filed a Form 4 on November 3, 2026, disclosing option exercises and open-market share sales conducted between October 30 and November 3, 2026, under a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: George J. Morrow, identified as a Director of Neurocrine Biosciences Inc (NASDAQ:NBIX).
  • Options exercised: A total of 15,000 Non-Qualified Stock Options were exercised across three dates at an exercise price of $53.64 per share, fully exhausting the option grant.
  • Shares sold: Multiple dispositions of common stock occurred between October 30 and November 3, 2026, at prices ranging from $144.32 to $169.10 per share.
  • Remaining beneficial ownership: Following all reported transactions, Morrow directly held 10,386 shares of common stock.
  • 10b5-1 plan: All dispositions were made pursuant to a Rule 10b5-1 trading plan adopted by Morrow on May 26, 2026.
  • Option grant origin: The exercised options were granted on May 22, 2017, vested in 12 equal monthly installments beginning June 22, 2017, and were scheduled to expire May 22, 2027.

Morrow Completes Full Exercise of 2017 Option Grant Over Three Trading Days

According to the filing, George J. Morrow exercised Non-Qualified Stock Options in three separate tranches: 300 shares on October 30, 2026; 7,500 shares on November 2, 2026; and 7,200 shares on November 3, 2026, each at the exercise price of $53.64 per share. These exercises collectively exhausted the option grant originally made on May 22, 2017, leaving zero derivative securities beneficially owned following the final transaction on November 3, 2026.

Concurrent with each exercise, the filing shows that shares were sold in the open market. On October 30, 300 shares were sold at $149 per share. On November 2, sales totaled 7,500 shares across three tranches at weighted average prices of $144.9751, $145.8591, and $146.7562, covering price ranges disclosed in the filing's footnotes. On November 3, eight separate sale transactions disposed of a combined 7,200 shares at prices ranging from $158.18 to a weighted average high of $168.5325, with individual transaction price ranges detailed in footnotes 5 through 10 of the filing.

The filing states that all dispositions "were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2026." The filing also notes that issuer policy restricts Morrow from amending or modifying the trading plan after adoption. Following all reported transactions, Morrow directly held 10,386 shares of Neurocrine Biosciences common stock. The form was signed by Darin Lippoldt as Attorney-in-Fact on November 3, 2026.

What Was Disclosed

Director George J. Morrow disclosed the exercise of 15,000 Non-Qualified Stock Options at $53.64 per share and the subsequent sale of 15,000 shares of Neurocrine Biosciences common stock between October 30 and November 3, 2026, under a pre-established 10b5-1 trading plan, leaving him with 10,386 shares directly owned.